These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 22594706

  • 1. A cost-effectiveness analysis of the effect of pregabalin versus usual care in the treatment of refractory neuropathic pain in routine medical practice in Spain.
    de Salas-Cansado M, Pérez C, Saldaña MT, Navarro A, Rejas J.
    Pain Med; 2012 May; 13(5):699-710. PubMed ID: 22594706
    [Abstract] [Full Text] [Related]

  • 2. An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings.
    de Salas-Cansado M, Pérez C, Saldaña MT, Navarro A, González-Gómez FJ, Ruiz L, Rejas J.
    Prim Care Diabetes; 2012 Dec; 6(4):303-12. PubMed ID: 22595032
    [Abstract] [Full Text] [Related]

  • 3. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study.
    Pérez C, Navarro A, Saldaña MT, Masramón X, Rejas J.
    Clin Ther; 2010 Jul; 32(7):1357-70. PubMed ID: 20678683
    [Abstract] [Full Text] [Related]

  • 4. A cost-utility study of the use of pregabalin added to usual care in refractory neuropathic pain patients in a Swedish setting.
    Prettyjohns M, Sandelin R, Lister S, Norrefalk JR.
    J Med Econ; 2012 Jul; 15(6):1097-109. PubMed ID: 22712872
    [Abstract] [Full Text] [Related]

  • 5. Costs and health resources utilization following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain: a post hoc analysis.
    Navarro A, Saldaña MT, Pérez C, Masramón X, Rejas J.
    Pain Pract; 2012 Jun; 12(5):382-93. PubMed ID: 22004531
    [Abstract] [Full Text] [Related]

  • 6. Clinical and resource utilization patterns in patients with refractory neuropathic pain prescribed pregabalin for the first time in routine medical practice in primary care settings in Spain.
    Pérez C, Navarro A, Saldaña MT, Masramón X, Pérez M, Rejas J.
    Pain Med; 2013 Dec; 14(12):1954-63. PubMed ID: 24330229
    [Abstract] [Full Text] [Related]

  • 7. Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium.
    Chevalier P, Lamotte M, Van Campenhout H, Eyckerman R, Annemans L.
    J Med Econ; 2013 Dec; 16(5):596-605. PubMed ID: 23409950
    [Abstract] [Full Text] [Related]

  • 8. Cost savings associated with early initiation of pregabalin in the management of peripheral neuropathic pain.
    Pérez C, Navarro A, Saldaña MT, Figueras-Balsells M, Muñoz-Tudurí M, Rejas J.
    Clin J Pain; 2013 Jun; 29(6):471-7. PubMed ID: 23328322
    [Abstract] [Full Text] [Related]

  • 9. Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain.
    De Salas-Cansado M, Álvarez E, Olivares JM, Carrasco JL, Ferro MB, Rejas J.
    Soc Psychiatry Psychiatr Epidemiol; 2013 Jun; 48(6):985-96. PubMed ID: 23086587
    [Abstract] [Full Text] [Related]

  • 10. A cost-consequences analysis of the effect of pregabalin in the treatment of peripheral neuropathic pain in routine medical practice in primary care settings.
    Navarro A, Saldaña MT, Pérez C, Torrades S, Rejas J.
    BMC Neurol; 2011 Jan 20; 11():7. PubMed ID: 21251268
    [Abstract] [Full Text] [Related]

  • 11. Effect of pregabalin in the treatment of refractory neck pain: cost and clinical evidence from medical practice in orthopedic surgery and rehabilitation clinics.
    Flórez-García M, Ceberio-Balda F, Morera-Domínguez C, Masramón X, Pérez M.
    Pain Pract; 2011 Jan 20; 11(4):369-80. PubMed ID: 21199310
    [Abstract] [Full Text] [Related]

  • 12. A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain.
    Gordon J, Lister S, Prettyjohns M, McEwan P, Tetlow A, Gabriel Z.
    J Med Econ; 2012 Jan 20; 15(2):207-18. PubMed ID: 22017236
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.
    Tarride JE, Gordon A, Vera-Llonch M, Dukes E, Rousseau C.
    Clin Ther; 2006 Nov 20; 28(11):1922-34. PubMed ID: 17213013
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia.
    Rodríguez MJ, Díaz S, Vera-Llonch M, Dukes E, Rejas J.
    Curr Med Res Opin; 2007 Oct 20; 23(10):2585-96. PubMed ID: 17875242
    [Abstract] [Full Text] [Related]

  • 15. Cost analysis of adding pregabalin or gabapentin to the management of community-treated patients with peripheral neuropathic pain.
    Sicras-Mainar A, Rejas-Gutiérrez J, Navarro-Artieda R, Planas-Comes A.
    J Eval Clin Pract; 2012 Dec 20; 18(6):1170-9. PubMed ID: 21883712
    [Abstract] [Full Text] [Related]

  • 16. Patient-reported outcomes in subjects with neuropathic pain receiving pregabalin: evidence from medical practice in primary care settings.
    Navarro A, Saldaña MT, Pérez C, Torrades S, Rejas J.
    Pain Med; 2010 May 20; 11(5):719-31. PubMed ID: 20345618
    [Abstract] [Full Text] [Related]

  • 17. Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin.
    Zhao Y, Sun P, Watson P.
    Curr Med Res Opin; 2011 Apr 20; 27(4):785-92. PubMed ID: 21303196
    [Abstract] [Full Text] [Related]

  • 18. A cost-consequences analysis of the effect of pregabalin in the treatment of painful radiculopathy under medical practice conditions in primary care settings.
    Saldaña MT, Navarro A, Pérez C, Masramón X, Rejas J.
    Pain Pract; 2010 Apr 20; 10(1):31-41. PubMed ID: 20629966
    [Abstract] [Full Text] [Related]

  • 19. Trigeminal neuralgia treated with pregabalin in family medicine settings: its effect on pain alleviation and cost reduction.
    Pérez C, Saldaña MT, Navarro A, Martínez S, Rejas J.
    J Clin Pharmacol; 2009 May 20; 49(5):582-90. PubMed ID: 19299534
    [Abstract] [Full Text] [Related]

  • 20. A cost-utility analysis of pregabalin in the management of peripheral neuropathic pain.
    Annemans L, Caekelbergh K, Morlion B, Hans G, De Cock P, Marbaix S.
    Acta Clin Belg; 2008 May 20; 63(3):170-8. PubMed ID: 18714847
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.